| Literature DB >> 32164227 |
Anna Skutnik-Radziszewska1, Mateusz Maciejczyk2, Iwona Flisiak3, Julita Krahel Urszula Kołodziej3,4, Anna Kotowska-Rodziewicz4, Anna Klimiuk5, Anna Zalewska5.
Abstract
Psoriasis is the most common inflammatory skin disease, characterized by the release ofproinflammatory cytokines from lymphocytes, keratinocytes, and dendritic cells. Although psoriasis is considered an immune-mediated inflammatory disease, its effect on secretory activity of salivary glands and quantitative composition of saliva is still unknown. The aim of this study was to evaluate the secretion of saliva as well as several selected inflammation and nitrosative stress biomarkers in unstimulated and stimulated saliva as well as plasma of psoriasis patients. We demonstrated that, with progressing severity and duration of the disease, the secretory function of the parotid and submandibular salivary glands is lost, which is manifested as decreased unstimulated and stimulated saliva secretion and reduced salivary amylase activity and total protein concentration. The levels of tumor necrosis factor-alpha (TNF-α), interleukin-2 (IL-2), and interferon-gamma (INF-α) were significantly higher, whereas interleukin-10 (IL-10) content was considerably lower in unstimulated and stimulated saliva of patients with psoriasis compared to the controls, and the changes increased with the disease duration. Similarly, we observed that the intensity of nitrosative stress in the salivary glands of psoriasis patients depended on the duration of the disease. By means of receiver operating characteristic (ROC) analysis, we showed that the evaluation of nitric oxide (NO), nitrotyrosine, and IL-2 concentration in non-stimulated saliva with high sensitivity and specificity differentiatedpsoriasis patients on the basis of the rate of saliva secretion (normal salivation vs. hyposalivation). In summary, the dysfunction of salivary glands in psoriasis patients is caused by inflammation and nitrosative stress.Entities:
Keywords: cytokines; nitrosative stress; plaque psoriasis; saliva; salivary glands
Year: 2020 PMID: 32164227 PMCID: PMC7141316 DOI: 10.3390/jcm9030745
Source DB: PubMed Journal: J Clin Med ISSN: 2077-0383 Impact factor: 4.241
Clinical characteristics of plaque psoriasis patients and control subjects.
| Patient Characteristics | Control | PN | PH | |
|---|---|---|---|---|
|
| Male | 23 (38.33%) | 13 (43.33%) | 10 (33.33%) |
| Female | 37 (61.67%) | 17 (56.67%) | 20 (66.67%) | |
|
| 52 ± 5 | 49 ± 6 | 51 ± 3 | |
|
| 172 ± 6 | 176 ± 3 | 169 ± 8 | |
|
| 75 ± 1 | 72 ± 3 | 74 ± 1 | |
| ND | 9.7 ± 3.4 | 18.52 ± 7.8 | ||
|
| ND | 10.39 ± 2.4 | 18.29 ± 4.6 | |
|
| <1 | ND | 18 (60%) | 6 (20%) |
| ≥1 | ND | 12 (40%) | 24 (80%) | |
|
| ||||
|
| 4.54 ± 0.54 | 4.23 ± 0.65 | 4.89 ± 0.87 | |
|
| 40.25 ± 6.5 | 42.45 ± 4.25 | 45.21 ± 0.89 | |
|
| 275 ± 56 | 245 ± 87 | 292 ± 23 | |
|
| 6.5 ± 2.2 | 7.05 ± 1.8 | 6.98 ± 1.86 | |
|
| 1.5 ± 0.5 | 8.56 ± 6.3 | 6.32 ± 7.56 | |
|
| 69 ± 9.8 | 72 ± 9.8 | 75 ± 6.5 | |
|
| 27.56 ± 12.3 | 24.36 ± 9.68 | 27.24 ± 6.35 | |
|
| 28.54 ± 12.25 | 30.23 ± 6.52 | 28.98 ± 8.64 | |
|
| ||||
|
| 20 ± 3 | 19 ± 6 | 21 ± 2 | |
|
| 0.2 ± 0.1 | 0.2 ± 0.2 | 0.1 ± 0.2 | |
|
| 1.5 ± 0.5 | 1.0 ± 0.5 | 1.0 ± 0.5 | |
|
| 0 | 0 | 0 | |
Abbreviations: ALT—alanine transferase; AST—aspartate transaminase; CRP—C-reactive protein; DMFT—decayed, missing, filled teeth index; GI—gingival index; Glc—D-glucose; HCT—hematocrit; n—number of patients; PASI—Psoriasis Area and Severity Index; PBI—papilla bleeding index; PLT—platelets; RBC—red blood cells; WBC—white blood cells. ND- not defined.
Figure 1Cytokine levels in unstimulated and stimulated saliva as well as plasma of plaque psoriasis patients with normal salivation and hyposalivation. Abbreviations: C—the control; IL-2—interleukin 2; IL-10—interleukin-10; INF-γ—interferon-gamma; ns—not significant; NWS—non-stimulated whole saliva; PN—psoriasis patients with normal salivation; PH—psoriasis patients with hyposalivation; SWS—stimulated whole saliva; TNF-α—tumor necrosis factor-alpha. * p < 0.05, ** p < 0.01, *** p < 0.001, and **** p < 0.0001.
Figure 2Nitrosative stress in non-stimulated and stimulated saliva as well as plasma of plaque psoriasis patients with normal salivation and hyposalivation. Abbreviations: C—the control; NO—nitric oxide; ns—not significant; NWS—non-stimulated whole saliva; PN—psoriasis patients with normal salivation; PH—psoriasis patients with hyposalivation; SWS—stimulated whole saliva. * p < 0.05, ** p < 0.01, *** p < 0.001, and **** p < 0.0001.
Figure 3Salivary gland function in plaque psoriasis patients and control subjects. Abbreviations: C—the control; NWS—non-stimulated whole saliva; ns—not significant; PN—psoriasis patients with normal salivation; PH—psoriasis patients with hyposalivation; SA—salivary amylase; SWS—stimulated whole saliva; TP—total protein. * p < 0.05, ** p < 0.01, *** p < 0.001, and **** p < 0.0001.
ROC analysis of the assessed cytokines and nitrosative stress biomarkers in the saliva of plaque psoriasis patients with normal salivation and hyposalivation.
| NWS | SWS | ||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Parameter | AUC | 95% Confidence Interval | Cut-Off | Sensitivity (%) | Specificity (%) | AUC | 95% Confidence Interval | Cut-Off | Sensitivity (%) | Specificity (%) | AUC | ||
|
| |||||||||||||
|
| 0.68 | 0.5417–0.8183 |
| >15.83 | 63.33 | 63.33 | 0.7311 | 0.6025–0.8597 |
| >5.717 | 66.67 | 66.67 | 0.5611 |
|
| 0.8111 | 0.7024–0.9198 |
| >6.789 | 73.33 | 73.33 | 0.6478 | 0.5071–0.7884 |
| >1.595 | 63.33 | 63.33 | 0.6122 |
|
| 0.7089 | 0.5760–0.8418 |
| <0.9704 | 63.33 | 63.33 | 0.7267 | 0.5997–0.8536 |
| <0.2410 | 66.67 | 66.67 | 0.6556 |
|
| 0.6622 | 0.5246–0.7999 |
| >4.358 | 60.00 | 60.00 | 0.6278 | 0.4848–0.7708 | 0.0891 | >1.142 | 60.00 | 60.00 | 0.5378 |
|
| |||||||||||||
|
| 0.77 | 0.6507–0.8893 |
| >318.90 | 66.67 | 66.67 | 0.6464 | 0.5443–0.7885 | 0.0556 | >224.00 | 60.71 | 60.00 | 0.5244 |
|
| 0.6844 | 0.5479–0.8209 |
| >42.73 | 60.00 | 60.00 | 0.7211 | 0.5857–0.8565 |
| >34.60 | 70.00 | 70.00 | 0.6644 |
|
| 0.7056 | 0.5744–0.8367 |
| >101.50 | 63.33 | 63.33 | 0.69 | 0.5569–0.8231 |
| >45.31 | 60.00 | 60.00 | 0.5744 |
|
| 0.7444 | 0.6120–0.8769 |
| >3398.00 | 70.00 | 70.00 | 0.6611 | 0.5223–0.8000 |
| >2139.00 | 60.00 | 60.00 | 0.5011 |
Abbreviations: AUC—area under the curve; C—the control; IL-2—interleukin 2; IL-10—interleukin 10; INF-γ—interferon-gamma; NO—nitric oxide; NWS—non-stimulated whole saliva; SWS—stimulated whole saliva; TNF-α—tumor necrosis factor-alpha.
ROC analysis of the assessed cytokines and nitrosative stress biomarkers in the plasma of plaque psoriasis patients with normal salivation and hyposalivation.
| Plasma | ||||||
|---|---|---|---|---|---|---|
| Parameter | AUC | 95% Confidence Interval | Cut-Off | Sensitivity (%) | Specificity (%) | |
|
| ||||||
|
| 0.5611 | 0.4135–0.7087 | 0.4161 | >3.748 | 50.00 | 50.00 |
|
| 0.6122 | 0.4685–0.7559 | 0.1354 | >7.201 | 60.00 | 60.00 |
|
| 0.6556 | 0.5127–0.7984 |
| >0.3863 | 63.33 | 63.33 |
|
| 0.5378 | 0.3897–0.6858 | 0.6152 | <251.20 | 50.00 | 50.00 |
|
| ||||||
|
| 0.5244 | 0.3743–0.6746 | 0.745 | >99.49 | 46.67 | 46.67 |
|
| 0.6644 | 0.5261–0.8028 |
| >57.03 | 60.00 | 60.00 |
|
| 0.5744 | 0.4261–0.7228 | 0.3219 | >302.90 | 60.00 | 60.00 |
|
| 0.5011 | 0.3528–0.6494 | 0.9882 | <3747.00 | 50.00 | 50.00 |
Abbreviations: AUC—area under the curve; C—the control; IL-2—interleukin 2; IL-10—interleukin 10; INF-γ—interferon-gamma; NO—nitric oxide; NWS—non-stimulated whole saliva; SWS—stimulated whole saliva; TNF-α—tumor necrosis factor-alpha.
Figure 4Receiver operating characteristic (ROC) analysis of nitric oxide, nitrotyrosine, and IL-2 in unstimulated saliva of plaque psoriasis patients with normal salivation and hyposalivation. IL-2—interleukin 2; NO—nitric oxide; NWS—non-stimulated whole saliva.
Statistically significant correlations in patients with plaque psoriasis.
| Pair of Variables | Group |
|
|
|---|---|---|---|
| NO NWS and NWS flow rate | PH | −0.68 | 0.001 |
| Peroxynitrite SWS and total protein SWS | PH | −0.56 | 0.0015 |
| TNF-α NWS and NWS flow rate | PH | −0.60 | 0.004 |
| IL-2 SWS and SWS flow rate | PH | −0.54 | 0.002 |
| Peroxynitrite NWS and amylase NWS | PN | −0.58 | 0.0008 |
| Peroxynitrite SWS and amylase SWS | PN | −0.68 | <0.0001 |
| TNF-α NWS and NO NWS | PH | 0.60 | 0.004 |
| IL-2 NWS and NO NWS | PN | 0.64 | 0.002 |
| TNF-α NWS and PASI | PH | 0.59 | 0.0006 |
| IL-2 NWS and PASI | PH | 0.63 | 0.0029 |
| Nitrotyrosine NWS and disease duration | PN | 0.53 | 0.003 |
| Nitrotyrosine SWS and disease duration | PN | 0.58 | 0.001 |
| Nitrotyrosine NWS and disease duration | PH | 0.61 | 0.004 |
| Nitrotyrosine SWS and disease duration | PH | 0.60 | <0.0001 |
Abbreviations: IL-2—interleukin 2; NO—nitric oxide; NWS—non-stimulated whole saliva; PN—psoriasis patients with normal salivation; PH—psoriasis patients with hyposalivation; SWS—stimulated whole saliva; TNF-α—tumor necrosis factor-alpha.